Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

Blood

Volumn 103, Issue 6, 2004, Pages 2284-2290

  Rosti, Gianantonio ^b   Martinelli, Giovanni ^b   Bassi, Simona ^b   Amabile, Marilina ^b   Trabacchi, Elena ^b   Giannini, Barbara ^b   Cilloni, Daniela ^b   Izzo, Barbara ^b   De Vivo, Antonio ^b   Testoni, Nicoletta ^b   Cambrin, Giovanna Rege ^b   Bonifazi, Francesca ^b   Soverini, Simona ^b   Luatti, Simona ^b   Gottardi, Enrico ^b   Alberti, Daniele ^b   Pane, Fabrizio ^b   Salvatore, Francesco ^b   Saglio, Giuseppe ^b   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; BCR ABL PROTEIN; BETA 2 MICROGLOBULIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DRUG RESPONSE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; LIVER TOXICITY; LUNG CARCINOMA; MAJOR CLINICAL STUDY; NEUTROPENIA; PAIN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN BINDING; RASH; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA;

EID: 12144290269     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2575     Document Type: Article

References (39)

1. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR/ABL positive cells. Nat Med. 1996;2:561-566.
2. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90: 4947-4952.
3. Buchdunger E, Cioffi CL, Law N, et al. The Abl protein-tyrosine kinase inhibitor, STI571, inhibits in vitro signal transduction mediated by c-Kit and PDGF receptors. Pharmacol Exp Ther. 2000;295: 139-145.
4. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
5. Deininger MW, Goldman JM, Lyndon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691-3698.
6. + leukemic cells and induces apoptosis. Blood Cells Mol Dis. 1997;23: 380-394.
7. Vigneri P, Wang JYJ. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7:228-234.
8. Holtz MS, Slovak ML, Zhang F, et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002;99:3792-3800.
9. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104.
10. le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst. 1999;91:163-168.
11. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
12. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344:1038-1042.
13. Kantarjian HM, Sawyers CL, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
14. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
15. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3538.
16. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547-3553.
17. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100: 1965-1971.
18. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
19. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood. 2003;102: 83-86.
20. Cross NCP, Hughes TP, Feng L, et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol. 1993;84:67-74.
21. Drobyski WR, Endean DJ, Klein JP, Hessner MJ. Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia. Br J Haematol. 1997;98:458-466.
22. Federl SF, Talpaz M, Kantarjian HM, et al. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood. 1999;93:2755-2759.
23. Chomel JC, Brizard F, Veinstein A, et al. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-α therapy or allogeneic bone marrow transplantation. Blood. 2000;95:404-409.
24. Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood. 2001;98:1701-1707.
25. Baccarani M, Russo D, Rosti G, Martinelli G. Interferon-alfa for chronic myeloid leukemia. Semin Hematol. 2003;40:22-33.
26. Van Dongen JJ, Gabert JA, Delabesse E, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901-1928.
27. Gabert J, Van Der Velden VH, Bi W, et al. Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer Program. Leukemia. 2003;17:2318-2357.
28. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation in each patient; II, analysis and examples. Br J Cancer. 1977;35:1-39.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
30. Rosti G, Trabacchi E, Bassi S, et al. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Hematologica. 2003;88:256-259.
31. Carella AM, Frassoni F, Melo J, et al. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica. 1997;82:478-495.
32. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
33. Hochhaus A, Reiter A, Saubele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-a therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood. 2000;95:62-66.
34. Martinelli G, Testoni N, Amabile M, et al. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy. Bone Marrow Transplant. 2000; 25:729-736.
35. Barret J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol. 2003; 40:59-71.
36. Mueller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA transcript expression in newly diagnosed CML patients treated with imatinib or interferon alpha [abstract]. Blood. 2002;100:1413a.
37. Hughes T, Kaeda J, Brandford S, et al. Molecular responses to imatinib (STI571) or interferon + Ara-C as initial therapy for CML: results in the IRIS study [abstract]. Blood. 2002;100:345a.
38. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet. 2003;4:75-85.
39. Goldman JM, Marin D. Management decisions in chronic myeloid leukemia. Semin Hematol. 2003; 40:97-103.